Citation Information :
Yadav R, Thakur MR. Dicyclomine and Mefenamic Acid Dependence: A Case Report and Review of Literature. Ind J Priv Psychiatry 2024; 18 (2):85-87.
Anticholinergic medicines, such as dicyclomine, are frequently prescribed as antispasmodics. In addition to its effects on the peripheral nervous system, dicyclomine also induces central anticholinergic effects due to its high penetration into the central nervous system. There have been reports of abuse or misuse of anticholinergic medicines, such as procyclidine, biperiden, benztropine, and trihexyphenidyl (Benzhexol). In this case report and review, we describe a case of an adolescent female who came to us with complaints of right lower quadrant abdominal pain, with imaging and other tests ruling out any structural cause for the last 7 years. She even underwent appendectomy 12–16 months before presenting to the hospital with complaints of pain which shifted to the left lower quadrant post appendicectomy. At the time of presentation, she was taking 200 mg of Tramadol and 3–4 tablets of fixed dose combination (FDC) of 250 mg mefenamic acid and 10 mg dicyclomine by a local chemist without any prescription. According to ICD-10, patient met criteria for abuse of non-psychoactive substances with co-morbid mental and behavioral disorders due to the use of opioids-dependence and moderate depression without somatic syndrome. This case illustrates the need to give attention toward the addiction potential of anticholinergics and the need to formulate a treatment plan for effective outcome.
Brown JH, Brandl K, Wess J. Muscarinic receptor agonists and antagonists. In: Goodman and Gilman's the Pharmacological Basis of Therapeutics. New York: McGraw Hill Foundation; 2017. pp. 149–162.
Janczura M, Kobus-Moryson M, Sip S, et al. Fixed-dose combination of NSAIDs and spasmolytic agents in the treatment of different types of pain—A practical review. J Clin Med 2021;10(14):3118. DOI: 10.3390/jcm10143118.
WHO. The ICD-10 Classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines. 1/Ed. World Health Organization 1994.
Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Res 2018;46(D1):D1074–D1082. DOI: 10.1093/nar/gkx1037.
Das S, Mondal S, Datta A, et al. A rare case of dicyclomine abuse. J Young Pharm 2013;5(3):106–107. DOI: 10.1016/j.jyp.2013. 08.004.
Sinha S, Dhiman S, Sidana A. A rare case of dicyclomine and mefenamic acid abuse fulfilling criteria of dependence syndrome. Indian J Psychiatr 2020;62(6):740–741. DOI: 10.4103/psychiatry.IndianJPsychiatry_562_19.
Singh VV, Gupta S, Sarkar S, et al. Problematic dicyclomine use: A case report and narrative review. Asian J of Psychiatr 2020;48(1):101891. DOI: 10.1016/j.ajp.2019.101891.
Giachetti A, Giraldo E, Ladinsky H, et al. Binding and functional profiles of the selective M1 muscarinic receptor antagonists trihexyphenidyl and dicyclomine. Br J Pharm 1986;89(1):83–90. DOI: 10.1111/j.1476-5381.1986.tb11123.x.
US Department of Health and Human Services. The neurobiology of substance use, misuse, and addiction [Internet]. Nih.gov. US Department of Health and Human Services; 2016. Available from: https://www.ncbi.nlm.nih.gov/books/NBK424849/.
Narcotics Drugs and Psychotropic Substances Act, 1985 [Internet]. 1985 Sep [cited 2024 Mar 5]. Available from: https://www.dor.gov.in/sites/default/files/Narcotic-Drugs-and-Psychotropic-Substances-Act-1985.pdf.
Drugs and Cosmetics (2nd Amendment) Rules. Available from: https://web.archive.org/web/20070221055138/http://drugscontrol.org/Schedule_H.pdf.